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SulTlnlary 
Natural killer cell stimulatory factor or interleukin 12 (NKSF/IL-12) is a heterodimeric cytokine 
produced by monocytes/macrophages, B cells, and possibly other accessory cell types primarily 
in response to bacteria or bacterial products. NKSF/IL-12 mediates pleiomorphic  biological activity 
on T  and NK cells and, alone or in synergy with other inducers, is a powerful stimulator of 
interferon 3' (IFN-3") production. IL-10 is a potent inhibitor of monocyte-macrophage  activation, 
that inhibits production of tumor necrosis factor ot (TNF-o  0, IL-1 and also IFN-3' from lymphocytes 
acting at the level of accessory cells. Because TNF-ot and IL-1 are not efficient inducers of IFN-3', 
the mechanism by which IL-10 inhibits IFN-3' production is not clear. In this paper, we show 
that  IL-IO  is  a  potent inhibitor of NKSF/IL-12  production from human peripheral blood 
mononuclear cells activated  with Staphylococcus aureus or lipopolysaccharide  (LPS).  Both the 
production of the free NKSF/IL-12 p40 chain and the biologically active p70 heterodimer are 
blocked by IL-10. NKSF/IL-12 p40 chain mRNA accumulation is strongly induced by S. aureus 
or LPS and downregulated by IL-10, whereas the p35 mRNA is constitutively expressed and 
only minimally regulated by S. aureus, LPS, or IL-10. Although IL-IO is able to block the production 
of NKSF/IL-12,  a powerful inducer of IFN-3' both in vitro and in vivo, the mechanism of inhibition 
of IFN-3' by IL-10 cannot be explained only on the basis of inhibition of NKSF/IL-12 because 
IL-10  can partially inhibit IFN-3' production induced by NKSF/IL-12,  and also, the IFN-3' 
production in response to various stimuli in the presence of neutralizing antibodies to NKSF/IL- 
12. Our findings that antibodies against NKSF/IL-12, TNF-o~, or IL-1~ can significantly inhibit 
IFN-3" production in response to various stimuli and that NKSF/IL-12 and IL-1B can overcome 
the IL-10-mediated inhibition of IFN-%  suggest that IL-10 inhibition of IFN-3' production 
is primarily due to its blocking production from accessory cells of the IFN-3'-inducer NKSF/IL- 
12, as well as the costimulating molecule IL-1/~. 
N 
'atural  killer cell stimulatory factor or interleukin 12 
(NKSF/IL-12) 1 is a heterodimeric cytokine produced 
by monocyte/macrophages, B cells, and possibly other acces- 
sory cell types primarily in response to bacteria or bacterial 
products (1-4).  NKSF/IL-12 is active on T  and NK cells, 
inducing cytokine production, proliferation, and enhanced 
cytotoxic activity (5-10). NKSF/IL-12 is particularly efficient 
in inducing IFN-3' production by T  and NK cells, and in 
this effect, it acts synergistically with other IFN-3'-inducers 
such as IL-2 and phorbol diesters in both NK and T cells; 
antigens, alloantigens, mitogens, and anti-CD3 Abs in T cells; 
1 Abbreviations used in this paper: NKSF, natural killer cell stimulatory 
factor; TPA, tetradecanoylphorbol  acetate. 
and target cells, immune complexes, and anti-CD16 Abs in 
NK  cells  (5,  11). Neutralizing  anti-NKSF/IL-12  Abs 
significantly and often completely inhibit IFN-3' production 
from human PBMC induced by several stimuli (e.g., Staphy- 
lococcus aureus, anti-CD3 Abs, PHA, and IL-2),  suggesting 
that NKSF/IL-12, either induced or constitutively produced, 
is required for optimal IFN-3' production by resting human 
lymphocytes (4). However, production of IFN-3" by activated 
NK or T cells, in the absence of NKSF/IL-12-producing cells, 
is not inhibited by anti-NKSF/IL-12 Abs (4). IL-12 also in- 
duces production of other cytokines by NK and T cells, in- 
cluding TNF-ol, although in this case, a synergistic effect 
with IL-2 is not observed (6). 
By a mechanism that is at least in part independent from 
IFN-3" production, IL-12 has been shown to induce a Th 
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IL-4-producing Th-2 cells, both in the response of human 
PBLs to allergens or bacterial antigens  (12),  and in the re- 
sponse of anti-OVA TCR transgenic mice to OVA (13). Im- 
portantly, in both systems (12, 13), anti-IL-12 Abs prevented 
Th-1 differentiation, suggesting that IL-12 is a necessary factor 
for Th-1  cell differentiation. 
IL-10 is a product of various cell types including mono- 
cytes and B and T cells, that, unlike IL-12, is associated with 
differentiation of Th-2 cells (14, 15). IL-10 inhibits lympho- 
cyte cytokine production, particularly IFN-% by T and NK 
cells, and also inhibits proliferation ofT cells, acting primarily 
at the level of monocyte/macrophage accessory cells (16-18). 
IL-10 is a potent inhibitor  of monocyte/macrophage func- 
tions, including oxidative burst, nitric oxide production, cy- 
totoxicity, and production of cytokines, such as TNF-c~ and 
IL-1  (19-24).  TNF-ot has  been shown to be an important 
cofactor for the induction of IFN-qr production by routine 
T  and NK cells,  and the ability of IL-10 to prevent TNF 
production by monocyte/macrophages has been proposed to 
be one of the mechanisms by which IL-IO inhibits  IFN-y 
production (25). However, TNF-oe by itself is unable to in- 
duce IFN-'y production, and cells other than monocytes and 
macrophages, including T and NK cells, also produce TNF-ot, 
making it unlikely that inhibition of TNF-o~ production by 
IL-10 may fully account for its effect on IFN-'/production 
(25). 
In this paper, we demonstrate that IL-10 efficiently inhibits, 
in addition to TNF-o~ and IL-13, IL-12 production by human 
PBMC.  Abs against  IL-12,  TNF-cr  and IL-1B and,  more 
effectively, their combinations, inhibit IFN-3' production from 
human PBMC in response to several different inducers.  IL- 
12 and IL-13, but not TNF-cr  are able to partially restore 
IFN-3' production in the presence of IL-10. These results sug- 
gest  that  IL-10  inhibits  IFN-3,  production  by preventing 
production by accessory cells of the IFN-3,-inducing cytokine 
NKSF/IL-12 and,  in part,  the costimulatory cytokines IL- 
13 and possibly TNF-a. 
Materials and Methods 
Cytokines  and  Reagents.  CHO  cell-activated  rNKSF/IL-12 
(5  x  1@ U/mg) was a gift from Dr. S. Wolf (Genetics Institute, 
Boston,  MA); rlL-l~ (3.8  x  107 U/ml) was provided by the Di- 
vision of Cancer Treatment (National Cancer Institute,  Bethesda, 
MD);  rlL-2 (107 U/mg) by Dr.  T.  Taguchi (Osaka University, 
Osaka, Japan); CHO cell-derived hlbl0 (1.5 x  107 U/rag) by Dr. 
K. Moore (DNAX, Palo Alto, CA), and TNF-c~ (5  x  107 U/mg) 
by Dr. H.M. Shepard (Genentech, South San Francisco, CA). The 
following  reagents  were  purchased  from  commercial  sources: 
PHA-M (Wellcome Diagnostics, Dartford, England); fixed S. aureus 
Cowan strain 1 (Pansorbin; Calbiochem-Behring  Corp., La Jolla, 
CA); LPS (from Escherichia toll, serotype 0127:B8; Sigma Chem- 
ical Co., St. Louis, MO); and 12-0-tetradecanoylphorbo113-acetate 
(TPA; Sigma Chemical Co.). 
Antibodies.  mAbs B154.2 (anti-TNF-ot, IgG1) and C8.6.2 (anti- 
NKSF/IL-12 p40, IgG1) were produced and characterized in our 
laboratory as previously described (4, 26). Neutralizing  anti-Ibl0 
mAb 19F1 was kindly provided by Dr. K. Moore and anti-Ibl/3 
F18.609 and F18.206 were kindly provided by Dr. M.A.  Cousin 
(Roussel-Uclaf, Romainville, France) (27). 
Cytokine Assays.  RIAs for human IFN-3~ and human TNF-c~ 
were  performed  as  previously  described  (26,  28)  using  mAbs 
B133.1/B133.5 and B154.9/B154.7, respectively. NKSF/Ib12 p40 
was measured in cell-free supernatants by RIA as described (4) using 
the mAb pairs Cll.79/C8.6.  RIA for IL-lfl was performed using 
F18.609/F18.206  mAbs (27). 
Quantitation of Biologically Active NKSF/IL-12 Heterodimer by an 
Ab Capture Bioassay.  The biological activity of NKSF/IL-12 was 
determined using a modification of the capture bioassay previously 
described (29). Briefly, the anti-NKSF/Ib12 p40 Ab Cll.5 (4) was 
absorbed (15 #g/ml,  100 #l/well, in 0.1 M carbonate buffer, pH 
9.5) for 24 h or longer at 4~  to bacteriological 96-well plates (Flow 
Laboratories, McLean, VA). The plates were washed three times 
with PBS and PBS/FCS 5% was added to plates (200/~1, I h, 37~ 
After three washes, dilutions of rNKSF/IL-12 standard or superna- 
tant fluids to be tested were added (100 #l/well, 3 h, room temper- 
ature),  the  plates  were  again washed  (five times)  and  PBMC 
(5  x  10S/well) together with 100 U/ml or rlL-2 were added to 
the plates. After an 18-h incubation  (37~  5% CO2), the super- 
natants were collected and tested for IFN-3' production  by RIA. 
The assay detects >~ 1 pg/ml of biologically active NKSF/II.,12, 
is specific for NKSF/II.-12, and at least in the concentration  range 
used in the present experiments,  is not affected by the presence 
of an excess of free p40 chains. 
Preparation of Human PBMC.  Peripheral blood obtained from 
healthy donors was anticoagulated with heparin. PBMC were sepa- 
rated on Ficoll-Hypaque (Lymphoprep; Nyegard and Co.,  Oslo, 
Norway) density gradient, and PBL were obtained after adherence 
of PBMC to plastic flasks (1 h, 37~  PHA blasts (>98% acti- 
vated T cells) were obtained after 5-d culture of PBL in the pres- 
ence of 1% PHA-M (5, 11). Pure preparations (>98%)of activated 
NK cells were purified from 8-d coculture of PBL with irradiated 
RPMI-8866 B lymphoblastoid cell line, as described (30, 31). Cul- 
tures were performed in 250 #1 RPMI 1640 medium supplemented 
with 10% heat-inactivated FCS (Irvine Scientific, Santa Aria, CA) 
in 96-well round-bottomed plates (Flow Laboratories) with  106 
cells/well. Reagents to be tested were added at the onset of the 
culture and supematants were harvested after 18 h, and 1040, TNF-c~, 
IL-1B, or IFN-y release were determined using specific RIAs.  In 
some experiments, neutralizing anti-NKSF/II.,121040 mAb (C8.6), 
anti-TNF-c~ mAb (B154.2), anti-ILl-~ (F18.609), at the concen- 
tration of 10/xg/ml each, were added to PBL during the 18-h cul- 
ture assays before harvesting the supernatants for the specific RIAs. 
Northern Blot Hybridization.  Northern blots were performed as 
already described (32). Briefly, total RNA was extracted from in- 
duced  and  uninduced  PBMC  by the  gnanidine  isothiocyanate 
method. Equal amounts  of RNA (15/zg/lane)  were fractionated 
in a 1%  agarose-formaldehyde gel. The genes were detected by 
sequential hybridizations of nylon membranes (Schleicher & Schuell, 
Keene,  NH)  to  32p-cDNA probes  for  NKSF/II~12  1040, p35, 
TNF-ot,  IL-I~,  and  ~-actin.  The  filters were  then  exposed to 
X-Omat AR film (Eastman Kodak Co., Rochester, NY) between 
double intensifying  screens (DuPont Co.,  Wilmington,  DE). 
RNAse Protection Assay.  The entire coding regions of p40- and 
p35-NKSF/IL-12 were amplified by PCR and subcloned into the 
pCRTM1000 pCRTMII vectors, respectively, according to the sug- 
gestions of the manufacturer  (Invitrogen  Co.,  San Diego,  CA). 
The vectors were linearized with appropriate restriction enzymes 
and  transcribed  using  32p-UTP (NEN;  DuPont  Co.)  and  the 
riboprobe kit (Promega Biotec, Madison, WI) into complemen- 
tary RNA (antisense) riboprobes containing  regions of 266 and 
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Figure  1.  Inhibition of cytokine production by human rlL-lO. PBMC 
were preincubated  for 4 h in the presence of the indicated  concentrations 
of human rlL-10 and then stimulated in the presence of rib10 with: 
(H)  LPS (1 #g/ml) or (0---0) S. ,ureus (1:10,000 wt/vol). After an 
18-h incubation at 37~  supematant fluids were collected  and tested for 
the presence  of II~12 p40, TNF-o(, and IL-I~ by KIA. All the experiments 
were performed in endotoxin-free conditions. Results are mean _+ SE, 
number of donors, ,  =  4. 
240 bp complementary to sequences in the p40 and p35 NKSF/IL- 
12, respectively. RNA samples (5-20/~g in 20/xl) were hybridized 
in solution with an excess of riboprobes (8-10  x  104 cpm, sp act 
109 cpm//~g, 90~  for 5 min, 42~  for > 10 h). 200 #1 of RNase 
solution  was added for 30 min at 37~  and the instructions  of 
the  Ribonuclease  Protection  Assay RPA II  Kit  (Ambion  Inc., 
Austin,  TX) were followed. The protected  fragments  were frac- 
tionated on 5% polyacrylamide/urea sequencing gels and detected 
by autoradiography. 
Results 
Inhibition  of lL-12 Production by IL-IO.  In endotoxin-free 
conditions, insignificant levels of NKSF/IL-12 1O40 are spon- 
taneously released by human PBMC in vitro (data not shown), 
whereas LPS or S. aureus are powerful inducers of NKSF/IL- 
12  production  (Fig.  1).  Human  rlL-10  induced  a  dose- 
dependent inhibition of NKSF/IL-12 production in response 
to either inducer which was almost complete at IL-10 con- 
centrations of 10--30 U/ml (Fig. 1). Murine rlL-10, inactive 
on human cells, did not inhibit NKSF/IL-12 production at 
concentrations  up  to  100 U/ml  (data not  shown).  When 
PBMC were separated into adherent (>95% monocytes) and 
monocyte-depleted, nonadherent  (<0.5% monocytes) popu- 
lations,  IL-IO inhibited  IL-12 production  in both prepara- 
tions (data not shown). In the nonadherent cell preparation, 
IL-12 is 1oroduced in part by B cells, although the major nonad- 
herent producer cells are HLA-DR +, non-B, nonmonocytic 
cells (4). At concentrations inhibitory for IL-12 production, 
IL-10 also inhibited LPS- and S. aureus-induced  TNF-ot and 
IL-1/~ production,  confirming and extending the results of 
other investigators  (21). 
The R.IA used to measure NKSF/IL-12 in Fig.  1 detects 
the 1040 chain either in free form or associated with the p35 
chain in the biologically active 1O70 heterodimer (4). Because 
PBMC always produce an excess of the free 1>40 chain over 
the 1070 heterodimer  (4), we tested whether IL-IO also in- 
hibits  the  production  of the  i070 heterodimer  using  an 
antibody-capture biological assay based on the ability of IL- 
12 captured by anti-IL-12  I>40 coated on plastic  to induce 
IFN-7 production from PBL in the presence of IL-2 (29). 
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Inhibition of NKSF/IIt12 production by rlL-lO. Human  Figure 2. 
PBMC from two donors were preincubated for 4 h in the presence of 10 
U/ml of rlL-10 and then stimulated  for 18 h with S. aureus  (1:10,000  wt/vol). 
Supernatant fluids were collected  and tested for the presence of IL-12 p70 
biologically  active heterodimer, Ab capture assay  (A), and IL-12  p40 double 
determinant RIA (B) as described in Materials and Methods. Each of the 
paired bars represents the results obtained from an individual donor. 
As shown in Fig. 2, IL-10 was found to inhibit production 
of both  the free 1O40 chain  and  the p70 heterodimer. 
We analyzed by Northern blotting the ability of IL-IO to 
inhibit S. aureus- (Fig. 3 A) and LPS-induced (data not shown) 
accumulation  of NKSF/IL-12  1040 and  TNF-c~  mRNA. 
S. aureus induced maximal accumulation of p40 mR.NA at 
3-5 h, whereas accumulation of TNF-ot mR.NA was max- 
imal at 1-3 h. At all time points analyzed,  50 U/ml IL-IO 
almost completely blocked S. aureus and LPS-induced accumu- 
lation of both p40 and TNF-o~ mRNA. Because p35 mRNA 
is at very low abundance,  RNase protection assay was used 
for its detection (Fig.  3 B). Unlike 1O40 mRNA,  that  was 
strongly induced by SAC stimulation  and inhibited by IL- 
10,  p35 mRNA accumulation  was only minimally  stimu- 
lated by SAC at 4-6  h  and also minimally  downregulated 
by IL-10. These results confirm previous data (4)  that  1035 
expression  is  constitutive  in  PBMC  and  only  minimally 
regulated. 
Role of NKSF/IL-12,  TNF-ce, and IL-1fl Production by Ac- 
cessory Cells in the Induction of lFN-7.  As shown in Fig. 4, 
IL-10  efficiently suppressed  IFN-7  production  by resting 
PBMC in response to IL-2, PHA, S. aureus, and, to a lesser 
extent, NKSF/IL-12. Abs to NKSF/IL-12 also significantly 
inhibited IFN-y production in the same experimental condi- 
tions.  However, the ability of IL-IO to still  inhibit  IFN-7 
production in the presence of anti-NKSF/IL-12 Abs (Fig. 4), 
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cumulation of IL-12 p40,  p35,  and TNF-~ mRNA in 
human PBMC.  Total RNA was extracted from PBMC 
incubated for the indicated times in tissue culture medium 
or in the presence orS. aureus (1:10,000 wt/vol) with or 
without 50 U/ml human riD10. (.4) Cells stimulated in 
the presence of II,10 were pretreated for 4 h with the same 
concentrations of Ibl0. The R.NA (15/~g/lane) was then 
hybridized in a Northern blotting with 32p-labeled  Ib12 
p40, TNF-c~, or ~-actin cDNA. Representative experi- 
ment out of four with similar results. (B) Total RNA from 
the RPMI-8866 cell line, constitutively expressing high 
levels of NKSF/Ib12 (1) and from PBMC incubated for 
4 h in medium, IblO 50 U/ml, S. aureus  (1:10,000  wt/vol), 
or S. aureus and IL-10, was hybridized with 3ZlXriboprobes 
transcribed from NKSF/IL-12 p40 and p35 cDNA. 20 #g 
RNA were used for hybridization with the p35 probe and 
5 #g with the p40 probe. Equivalency  of  the different  RNA 
preparations was determined by optical density and by hy- 
bridization with a B-actin probe in a Northern blotting 
(data not shown), mRNA accumulation was quantitated 
by RNase protection and autoradiograms showing the pro- 
tected RNA fragment  (240 bp for p35 and 266 bp for 
p40) are presented. Representative  experiment out of three 
with similar results. All the experiments shown in this 
figure were performed in endotoxin-free conditions. 
suggested that IL-10-mediated inhibition of IFN-~ produc- 
tion was not solely due to suppression  of NKSF/IL-12 produc- 
tion. We therefore investigated the role in IFN-3' production 
of two other cytokines inhibited by IL-10, IL-I~, and TNF-c~. 
Neutralizing Abs against NKSF/IL-12, TNF-ot, and IL-I~ 
at least partially inhibited IFN-3' production individually (Fig. 
5). IL-2, IL-12, and TPA-induced IFN-3, production also on 
purified preparations  of cultured NK and T  cells, whereas 
S. aureus, which presumably  acts indirectly by stimulating 
accessory cells to produce NKSF/IL-12 (4), was unable  to 
induce IFN-3' by the purified cell preparations.  The IFN-y 
production by purified activated NK and T cells in response 
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Figure 4.  Effect  of rib10 and neutralizing Abs anti-NKSF/lb12 on 
IFN-3' production by human PBMC in response  to various  inducers. Human 
PBMC were incubated (5  x  106/ml, 18 h, 37~  with or without human 
rile10 (PBMC stimulated in the presence of Ibl0 were also preincubated 
for 4 h in the presence  of the same 11,10 concentration) and with or without 
anti-NKSP/IL-12 (C8.6,  10/~g/ml). The cell-free supernatant  fluid was 
then assayed for IFN-3, content by RIA. Results are mean _+ SE, n  =  6. 
to IL-2, IL-12, and TPA was not inhibited by IL-10, unlike 
the significant inhibition observed in the same conditions with 
resting PBMC (Fig. 6). The inability of IL-IO to suppress 
IFN-3, in the purified activated cell preparations  was likely 
due to the absence of accessory cells which are required for 
IFN-y production by resting but not by activated lympho- 
cytes (5). Addition of cultured monocyte-derived macrophages 
to the purified NK and T cells in most experiments  recon- 
stituted the ability of the cells to produce IFN-3' in response 
to S. aureus and enhanced the production in response to IL-2 
or IL-12. The IFN-3' production in response to S. aureus or 
the enhanced production of IFN-3'  in response to IL-2 or 
IL-12 in the presence of macrophages was inhibited by IL-10 
(data not shown). Purified NK and T cell preparations were 
unable to produce NKSF/IL-12 (4) and anti-NKSF/IL-12 Abs 
failed to inhibit IL-2 or TPA-induced IFN-3, production in 
purified NK cells (Fig. 7) and T cells (data not shown), un- 
like what was observed with PBMC (Fig. 4). The enhanced 
IFN-3' production in response to S. aureus obtained by adding 
monocyte-derived macrophages to NK or T cells, was, how- 
ever, inhibited by anti-NSKF/IL-12 Abs. Anti-TNF-c~ Abs, 
unlike anti-NKSF/IL-12, significantly  inhibited IFNw produc- 
tion in response to IL-2, NKSF/IL-12, and TPA in purified 
NK (Fig. 7) and T  cells (data not shown), indicating that 
TNF-c~, known to be produced by NK and T  cells in re- 
sponse to  these  stimuli (6,  26,  31), participates  in IFN-3, 
production not only by resting,  but also by activated NK 
and T  cells. 
NKSF/IL-12 and IL-I~ Reconstitute IFN-~ Production in the 
Presence of IL-IO.  The observation  that  neutralizing Abs 
against  NKSF/IL-12, TNF-o~, and IL-I~ inhibited IFN-3, 
production by PBMC in response to various stimuli, prompted 
us to test  the ability  of these three cytokines  to stimulate 
IFN-3, production and to prevent IL-10 inhibition. To de- 
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Figure  5.  Effect of neutralizing Abs anti-NKSF/Ib12, 
anti-TNF-cx,  and  anti-IL-1B on  IFN-?  production  by 
human PBMC in response to various inducers.  Human 
PBMC were incubated  (5  x  106/mI, 18 h, 37~  with 
various IFN-3' inducers (IL-2, 100 U/ml; IL-12, 1 ng/ml; 
S. aureus,  1:10,000 vol/vol; PHA, 1%; anti-CD3 and mAb 
OKT3, and the indicated combinations of anti-NKSF/IL-12 
(C8.6, 10/~g/ml) anti-TNP-cx (B154.2, 10/~g/ml) or anti- 
IL-1B (F18.609, 10 t.tg/ml) Abs. The cell-free supernatant 
fluid was then assayed for IFN-'y content by ILIA. Results 
are mean  _+  SE, n  =  4. 
crease the constitutive production of these cytokines,  their 
effect was tested in endotoxin-free conditions. In these con- 
ditions, fiN-? production was found to be consistently lower 
than that  observed  when nonendotoxin tested lots of PBS 
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Figure  6.  Effect of rlL-t0 on IFN-3~ production by purified  prepara- 
tions  of activated NK calls (A), T cells (B), and resting PBMC (C), in 
response to various stimuli.  Purified NK cells from 8-d cocultures of PBL 
stimulated with irradiated RPMI-8866 ceUs, purified T cells from 5<1 PHA- 
stimulated  cultures  of PBMC, and total resting PBMC were incubated 
(18 h, 5  x  106 cdls/ml, 37~  in medium or in the presence orS. aureus 
(1:10,000 wt/vol), rib2 (100 U/m1), rNKSF/Ib12 (1 rig/m1), or TPA 
(10 -s M), and in the presence (during the incubation and a 4-h pretreat- 
ment) or absence of 50 U/m1 human rlL-10. CeU-free supernatant  fluids 
were then collected and assayed for IFN-'y content by ILIA. Results  are 
expressed as mean  +  SE, n  =  7 for NK and T cells, n  =  4 for PBMC. 
and FCS were used, suggesting that activation  of accessory 
cells  by contaminant endotoxin has an enhancing role  on 
IFN-'y  production by PBMC.  To obtain consistently mea- 
surable levels of IFN-'y in these experiments,  100 U/ml of 
rlL-2 were added. In these conditions, NKSF/IL-12, but not 
TNF-ot or IL-I~ induced IFN-'y production (Fig. 8). IL-I~ 
but not TNF-c~ (tested in a range of concentrations from 
1 to 30 U/ml), slightly enhanced IFN-'y production induced 
by NKSF/IL-12 and IL-2. IL-10 (10 U/ml) inhibited IFN-~/ 
production induced by NKSF/IL-12 and IL-2, and this inhi- 
bition was largely reversed by the addition of 10 ng/ml IL- 
13,  whereas  addition of TNF-o~  had no effect  (Fig.  8). 
Discussion 
IL-10  was shown to inhibit macrophage  activation  and 
production of cytokines such as TNF-c~ and IL-1  (19-24). 
IL-IO can  also  inhibit T  cell  lymphokine production and 
proliferation  by suppressing  the function of accessory  and 
APCs (16).  IL-10 inhibits the accessory function of macro- 
phages, but not of other APCs such as dendritic or B cells, 
by suppressing both secretion of costimulatory cytokines and 
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Figure  7.  Anti-TNF-o~, but not anti-NKSF/IL.12  Abs inhibit IFN-3, 
production by purified cultured NK cells in response to various inducers. 
NK cells were purified from 8<lcocultures of PBMC with irradiated RPMI- 
8866 B cells and stimulated  for 18 h with rIL-2 (100 U/ml), rNKSF/II.-12 
(1 ng/ml), or TPA (10 -s M), in the presence or absence of anti-NKSF/Ib 
12 (C8.6,  10/lg/ml) or anti-TNF-cx (B154.2,  10/~g/ml) Abs.  Cell-free 
supernatant  fluids were collected and assayed for IFN-'y content by ILIA. 
Results  are expressed as mean  _+  SE, n  =  5. 
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Figure 8.  Effect  of rlL-1/3 and rTNF-c~  on the inhibitory  effect  of IL-10 
on the IFN-3' production  by PBMC in response  to various  concentrations 
of rNKSF/IL-12. PBMC were purified and incubated (5 x 106/ml, 18 h, 
37~  100 U/ml rlL-2) in endotoxin-free  conditions  at the indicated  con- 
centrations of rNKSF/IL-12 and in the absence (.4) or in the presence  of 
t ng/ml (B) or 10 ng/ml (C) rlblB, in medium  (o---o), or in medium 
containing 10 U/ml human  rlbl0 (including  a 4-h pretreatment  with IL- 
10) (~--4), 30 U/ml rTNF-ot  (zx  zX);  30 U/ml rTNF-cq and 10 U/ml 
rlbl0 (-"  g,). Cell-free  supernatant  fluids were  coUected  and assayed  for 
IFN-3' content by ILIA. Results are expressed as mean _+ SE, n  =  3. 
expression of costimulatory molecules (e.g., B7) on the mac- 
rophage surface (33).  The ability of IL-10 to inhibit IFN-y 
production by T  and NK cells is not easily explained by its 
inhibition of cytokines such as TNF-~ and IL-1, which have 
costimulatory or enhancing effects on IFN-3, production, but 
which by themselves are not able to induce IFN-? produc- 
tion (25). 
We (1, 4, 5, 11) have reported that NKSF/IL-12, a product 
of monocytes/macrophages and other accessory cells,  is  a 
powerful inducer of IFN-'7 production by NK and T cells, 
acting alone or in synergy with IL-2 or other IFN-'y inducing 
stimuli. NKSF/IL-12 has a major role in IFN-y production 
by human PBL in vitro. When IFN-3' production is induced 
by stimuli able to induce monocytes to produce NKSF/IL- 
12, such as S.  aureus or other bacteria or bacterial products, 
anti-NKSF/IL-12  Abs  almost  completely  abolish  IFN-3~ 
production (4).  However, a significant inhibition of IFN-'y 
production by anti-NKSF/IL-12 Abs is also observed when 
IFN-'y inducers are used such as IL-2 or PHA, that are not 
able to significantly induce NKSF/IL-12 production. These 
results, therefore, suggest that NKSF/IL-12,  constitutively 
produced or possibly induced by contaminant endotoxin, plays 
a major role in IFN-3' production. Similarly, in the murine 
system,  it  was  shown  that  NKSF/IL-12  is  required  for 
Toxoplasma-induced IFN-'y production in vitro (34) and we 
(Wysocka, M., and G. Trinchieri, unpublished observations) 
have observed that anti-NKSF/IL-12 mAbs block LPS-induced 
IFN-3' production in vivo in mice. Because of this central 
role of NKSF/IL-12 in IFN-'y production, we investigated 
the effect of IL-10 on the ability of monocytes to produce 
NKSF/IL-12. Similarly to what was previously reported for 
TNF-ot,  IL-1,  and  other monokines (21-23),  IL-IO  very 
efficiently suppressed in PBMC IL-12 p40 mRNA accumu- 
lation and secretion of IL-12 p40 free chain and p70 hetero- 
dimers induced by LPS or S. aureus. Production of NKSWIL-12 
from both monocytes and nonadherent mononuclear cells was 
suppressed by IL-IO.  Because B ceils apparently are respon- 
sible for only a fraction of NKSWIL-12 production by nonad- 
herent mononuclear cells and the nature of the NKSF/IL-12 
producer HLA-DR + nonadherent cells remains to be deter- 
mined (4), it is not possible  to conclude yet on which cells, 
in  addition  to  monocytes,  IL-IO  is  active  in  suppressing 
NKSF/IL-12 production. 
Although NKSF/IL-12 plays a major role both in in vitro 
and in vivo induction of IFN-3' production in response to 
various stimuli, IL-10-mediated inhibition of IFN-? cannot 
be explained only by inhibition of NKSWIL-12 production 
by accessory ceils, because of the ability of IL-10 to at least 
partially suppress  IFN-3' production by PBMC in response 
to NKSF/IL-12.  We therefore analyzed the possibility that 
inhibition of other cytokines, such as TNF-c~ and IL-1/3, play 
a role in the effect of IL-IO on IFN-"/production. Although 
TNF-ee and  IL-I~,  unlike NKSF/IL-12,  did not directly 
stimulate IFN-3' production, neutralizing Abs against these 
cytokines significantly suppressed IFN-? production,  sug- 
gesting that they are required costimulatory factors for IFN-? 
production. Only IL-1/3 and not TNF-ot was shown to be 
able to prevent the ability of IL-10 to inhibit IFN-? produc- 
tion in response to NKSF/IL-12. We interpret these data to 
indicate that IL-10 inhibits IFN-? production in PBMC by 
suppressing both NKSF/IL-12 and IL-1 production by mono- 
cytes and other accessory cells. Although TNF-c~ is also an 
important cofactor for IFN-y production and IL-10 inhibits 
its production by monocytes, it appears  not to play a pri- 
mary role in the effect of IL-10 on IFN-3' production, prob- 
ably because upon induction with IL-2, NKSF/IL-12 or other 
stimuli, TNF-t~ is produced not only by monocytes but also 
by NK and T  cells, not affected by IL-10.  This conclusion 
is supported by the observation that IFN-3' production by 
purified preparations of NK and T cells is partially inhibited 
by anti-TNF-c~ Abs, but is unaffected by IL-10 or by anti- 
NKSF/IL-12 Abs. Another possible mechanism of action of 
IL-IO, not investigated in this study, could be mediated by 
its effect on costimulatory molecules on the membrane of 
accessory cells  (33).  For  example,  we  have  observed that 
costimulation of T cells with anti-CD28 Abs or B7 antigen 
on accessory cells synergizes with NKSF/IL-12 in inducing 
IFN-3, production (Kubin, M.,  and G. Trinchieri, unpub- 
lished observations). 
The ability of IL-10  to inhibit NKSF/IL-12 production 
has particular interest in light of the opposite effects of these 
two cytokines on Th-l-Th-2 cell differentiation (12, 13). Be- 
cause NKSF/IL-12 may be an obligatory factor for efficient 
Th-1 responses (12,  13), IL-10 production by Th-2 cells or 
by monocytes may represent a feedback mechanism preventing 
differentiation of Th-1 clones and favoring the maintenance 
1046  Interleukin  10 Inhibits Interleukin 12 Production of a Th-2 response. The understanding of the reciprocal regu- 
lation of these cytokines in vitro and in vivo will shed light 
on the regulation of cellular and humoral immune responses 
and will possibly provide means of therapeutic intervention 
for modulating them. 
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